IRCT20171122037571N1 IRCT 2019-03-05 Arya Tina Gene company ِDetermining efficacy and safety of recombinant growth hormone Somatin® (AryaTinaGene) compared to Norditropin® (Novonordisk) in children with growth hormone deficiency ِDetermining efficacy and safety of recombinant growth hormone Somatin® (AryaTinaGene) compared to Norditropin® (Novonordisk) in children with growth hormone deficiency: A non-inferiority phase III randomized parallel clinical trial 2019-05-05 anticipated 80 Complete https://irct.ir/trial/37419 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random Chain Generation performed using by (https://www.sealedenvelope.com)We used randomized permutations, blocks (the size of each block is 4) for a total of 80 volunteers (1: 1 ratio). The codes will be labeled on the drugs. After ensuring the volunteer's eligibility and signing the informed consent form, a nurse will receive a code from the study site which will be used for random allocation of the drug to the candidate. The related drug will be used for the volunteer. In this way, the volunteers fall into one of the two intervention groups and the volunteers' group and the type of drug they receive will not be disclosed to researchers or the study team, Blinding description: In this clinical trial, blindness can not be fully accomplished (due to the brand's exclusive form of this drug, this is not possible for any study), but we try to minimize the information sources for different individuals in the study to prevent the Information bias. For this purpose, syringes containing both drugs are packaged with code only. Researchers who prescribe medication, those who provide the drug to patients, and those who are responsible for the examination and evaluation of patients, will be unaware of the nature of the syringes, and during this study. 3 Short stature due to endocrine disorder. Intervention 1: Intervention group: AryaTinaGen recombinant Growth Hormone, 35µg/kg/d, subcutaneous injection. Intervention 2: Control group: Norditropin recombinant Growth Hormone 35 µg/kg/d, subcutaneous injection. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no more information